Blood advances
Journal
Overview
publication venue for
-
A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN.
2020
-
Thyroid hormones contribute to JAK/STAT pathway abnormal activation promoting T-cell lymphoma dissemination.
2025
-
Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation..
9.
2025
-
Real-World Survival Outcomes in First-Line Ibrutinib-Treated Patients with High-Risk CLL/SLL.
2025
-
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry..
9.
2025
-
Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia..
9.
2025
-
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study..
9.
2025
-
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma.
2025
-
Anxiety and depression in patients with histiocytic neoplasms and their associated clinical features..
9.
2025
-
Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022.
2025
-
IDCH: is it now determined?.
9.
2025
-
High Pulmonary Hypertension Risk by Echocardiogram Shortens Survival in Polycythemia Vera.
2024
-
Deficit accumulation frailty index (DAFI) and treatment tolerability in AML: Data from CALGB 11001 and 11002 (Alliance).
2024
-
Treatment Patterns and Outcomes in Follicular Lymphoma with POD24: An Analysis from The LEO Consortium.
2024
-
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy..
8.
2024
-
Polygenic polymorphism is associated with NKG2A repertoire and influences lymphocyte phenotype and function..
8.
2024
-
What is in a name: defining pediatric refractory ITP..
8.
2024
-
Outcomes in Children with Provoked Venous Thrombosis and Antiphospholipid Antibodies: Findings from the Kids-DOTT Trial.
2024
-
Targeting T cells with tetravalent bispecific antibodies for the treatment of graft versus host disease.
2024
-
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts..
8.
2024
-
Evaluating Lab-Based Eligibility Criteria by Race/Ethnicity in Clinical Trials of Diffuse Large B-Cell Lymphoma.
2024
-
Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib..
8.
2024
-
Absolute Lymphocyte Count after BCMA CAR-T Therapy is a Predictor of Response and Outcomes in Relapsed Multiple Myeloma.
2024
-
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis..
8.
2024
-
Defining Primary Refractory Large B-cell Lymphoma.
2024
-
Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
2024
-
Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data.
2024
-
An indirect comparison of acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive CLL.
2024
-
Myeloablative Vs. Non-Myeloablative Consolidation for Primary Central Nervous System Lymphoma: Results of Alliance 51101.
2024
-
Somatic mutations in FAS pathway increase hemophagocytic lymphohistiocytosis risk in T- and/or NK-cell lymphoma patients.
2024
-
Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database..
8.
2024
-
Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma..
8.
2024
-
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
2024
-
Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes..
8.
2024
-
Acute Pulmonary Injury in Hematology Patients Supported with Pathogen Reduced and Conventional Platelet Components.
2024
-
Racial/ ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation.
2024
-
Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study.
2024
-
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML..
8.
2024
-
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial.
2024
-
Mutations Highly Specific for Secondary AML are Associated with Poor Outcomes in ELN Favorable Risk NPM1-mutated AML.
2024
-
High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer.
2024
-
Histiocytic neoplasm subtypes differ in their MAP2K1 mutational type..
7.
2023
-
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms..
7.
2023
-
Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant..
7.
2023
-
Gender disparities in allograft access due to HLA-sensitization in multiparous women.
2023
-
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies..
7.
2023
-
Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma..
7.
2023
-
The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression..
7.
2023
-
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
2023
-
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories..
7.
2023
-
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis..
7.
2023
-
Emergence of human CMV-induced NKG2C+ NK cells is associated with CD8+ T-cell recovery after allogeneic HCT..
7.
2023
-
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma..
7.
2023
-
Resistance to PRMT5 Targeted Therapy in Mantle Cell Lymphoma.
2023
-
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation..
7.
2023
-
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303..
7.
2023
-
Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia..
7.
2023
-
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia..
7.
2023
-
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma..
7.
2023
-
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy..
7.
2023
-
Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia..
7.
2023
-
Association between non-European ancestry, low socioeconomic status, and receipt of HLA-disparate allografts in adult BMT recipients..
7.
2023
-
Clonal hematopoiesis in survivors of childhood cancer..
7.
2023
-
Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation..
7.
2023
-
PRMT5 Inhibition Drives Therapeutic Vulnerability to Combination Treatment with BCL-2 Inhibition in Mantle Cell Lymphoma.
2023
-
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma..
7.
2023
-
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates..
7.
2023
-
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
2023
-
How I read an article that uses machine learning methods.
2023
-
Flow cytometric assessment of leukemia-associated monocytes in childhood B-cell acute lymphoblastic leukemia outcome.
2023
-
FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells..
7.
2023
-
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia..
7.
2023
-
Brentuximab Vedotin Following Autologous Transplantation in Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma.
2023
-
Aberrant expression of GOLM1 protects ALK+ anaplastic large cell lymphoma from apoptosis by enhancing BCL-XL stability.
2023
-
Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults..
6.
2022
-
RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS..
6.
2022
-
Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models.
2022
-
Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARα Agonist, is a Novel Approach in AML.
2022
-
Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones.
2022
-
Racial disparities in access to alternative donor allografts persist in the era of "donors for all"..
6.
2022
-
An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS).
2022
-
Patient perspectives on testing for clonal hematopoiesis of indeterminate potential.
2022
-
Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy..
6.
2022
-
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma..
6.
2022
-
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
2022
-
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen..
6.
2022
-
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment..
6.
2022
-
Cell origin-dependent cooperativity of mutant Dnmt3a and Npm1 in clonal hematopoiesis and myeloid malignancy..
6.
2022
-
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients
2022
-
Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis.
2022
-
A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome..
6.
2022
-
Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness..
6.
2022
-
Myb drives B-cell neoplasms and myeloid malignancies in vivo..
6.
2022
-
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey..
6.
2022
-
Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn..
6.
2022
-
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML..
6.
2022
-
Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML..
6.
2022
-
Geriatric assessment for older adults receiving less intensive therapy for acute myeloid leukemia: Report of CALGB 361101.
2022
-
Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency..
6.
2022
-
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT..
6.
2022
-
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.
2022
-
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation..
6.
2022
-
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia..
6.
2022
-
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML..
6.
2022
-
Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma..
5.
2021
-
ALCAM-EGFR interaction regulates myelomagenesis..
5.
2021
-
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies..
5.
2021
-
PD-1 inhibition in advanced myeloproliferative neoplasms..
5.
2021
-
Restriction of HIV-1 infection in sickle cell trait..
5.
2021
-
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma..
5.
2021
-
Evolving Frontline Immunochemotherapy for Mantle Cell Lymphoma and the Impact on Survival Outcomes.
2021
-
Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome..
5.
2021
-
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease..
5.
2021
-
IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS..
5.
2021
-
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells..
5.
2021
-
Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy.
2021
-
Loss of erythroblasts in acute myeloid leukemia causes iron redistribution with clinical implications..
5.
2021
-
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis..
5.
2021
-
Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation..
5.
2021
-
Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML..
5.
2021
-
Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis..
5.
2021
-
ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML..
5.
2021
-
Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML..
5.
2021
-
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML..
5.
2021
-
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19..
5.
2021
-
Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses..
5.
2021
-
Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma..
5.
2021
-
A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant..
5.
2021
-
High progression-free survival after intermediate intensity double unit cord blood transplantation in adults..
4.
2020
-
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease..
4.
2020
-
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub..
4.
2020
-
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis..
4.
2020
-
The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development..
4.
2020
-
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma..
4.
2020
-
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response..
4.
2020
-
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes..
4.
2020
-
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase..
4.
2020
-
HLA-A alleles influencing NK cell function impact AML relapse following allogeneic hematopoietic cell transplantation..
4.
2020
-
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma..
4.
2020
-
JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs..
4.
2020
-
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies..
4.
2020
-
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality..
4.
2020
-
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report..
4.
2020
-
Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML..
4.
2020
-
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure..
4.
2020
-
Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms..
4.
2020
-
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML..
4.
2020
-
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia..
4.
2020
-
CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma..
4.
2020
-
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA..
4.
2020
-
Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia..
4.
2020
-
Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk..
4.
2020
-
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management..
4.
2020
-
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation..
4.
2020
-
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL..
4.
2020
-
Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin..
4.
2020
-
Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents..
3.
2019
-
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes..
3.
2019
-
Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor..
3.
2019
-
Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells..
3.
2019
-
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants..
3.
2019
-
Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma..
3.
2019
-
Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia..
3.
2019
-
Challenges and approaches to implementing master/basket trials in oncology..
3.
2019
-
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition..
3.
2019
-
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning..
3.
2019
-
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies..
3.
2019
-
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission..
3.
2019
-
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL..
3.
2019
-
Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia..
3.
2019
-
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib..
3.
2019
-
Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms..
3.
2019
-
CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking..
3.
2019
-
A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease..
3.
2019
-
Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis..
3.
2019
-
Targeting CD47 in Sézary syndrome with SIRPαFc..
3.
2019
-
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma..
3.
2019
-
Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma..
3.
2019
-
Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults..
3.
2019
-
B-cell tumor development in Tet2-deficient mice..
2.
2019
-
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)..
2.
2018
-
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas..
2.
2018
-
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms..
2.
2018
-
PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation..
2.
2018
-
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia..
2.
2018
-
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802..
2.
2018
-
In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance..
2.
2018
-
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort..
2.
2018
-
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission..
2.
2018
-
A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia..
2.
2018
-
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort..
2.
2018
-
Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis..
2.
2018
-
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma..
2.
2018
-
Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity..
2.
2018
-
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia..
2.
2018
-
The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles..
2.
2018
-
Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy..
1.
2017
-
Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review..
1.
2017
-
The clinical spectrum of Erdheim-Chester disease: an observational cohort study..
1.
2017
-
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma..
1.
2016
-
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment..
1.
2016
-
Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma..
3.
2019
-
Inaccuracies in assignment of patient race and ethnicity: implications for unrelated donor searches and health care delivery.
2023
-
Under AI's lens: spotting mutations visually..
8.
2024
-
Optimizing liver health before and after gene therapy for hemophilia A.
2024
-
Retrospective characterization of nodal marginal zone lymphoma.
2023
-
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.
2018
-
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients.
2025
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)